Skip to main content
Erschienen in: Acta Diabetologica 3/2015

01.06.2015 | Original Article

Persistence and adherence to oral antidiabetics: a population-based cohort study

verfasst von: Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault

Erschienen in: Acta Diabetologica | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims

A population-based cohort study design was used to estimate persistence rate, re-initiation rate after discontinuation, and adherence level among incident users of oral antidiabetics (OADs), and to investigate predictors of non-persistence and non-adherence.

Methods

Incident OAD users were identified using healthcare databases of residents covered by the public drug insurance plan of the Province of Quebec, Canada. Patients initiated OAD therapy between January 2000 and October 2009 and were aged 45–85 years at cohort entry. Persistence rate, re-initiation after discontinuation, and adherence level were assessed over 2 years. Predictors of non-persistence and non-adherence were analyzed using Cox and logistic regression models, respectively.

Results

The cohort included 160,231 incident OAD users at entry. One year after OAD initiation, persistence rate was 51 % and adherence level 67 %. Among those deemed non-persistent, 80.6 % re-initiated OAD therapy within 12 months of discontinuation; a proportion increasing with primary persistence duration. The 1-year persistence rate varied according to OAD classes; being the highest for thiazolidinediones (62 %) and the lowest for alpha-glucosidase inhibitors (30 %). The likelihood for non-persistence was 39–54 % higher when drug copayments were required. Conversely, OAD discontinuation was least likely for patients with schizophrenia [hazard ratio 0.70 (95 % CI 0.67–0.73)], dyslipidemia [0.85 (0.84–0.87)], anticoagulation [0.86 (0.83–0.88)], hypertension [0.87 (0.85–0.88)], and ≥7 medications [0.90 (0.88–0.91)]. Predictors of non-adherence were similar.

Conclusions

Non-persistence and non-adherence to OAD therapy were common, although re-initiation rate was high. OAD classes, drug copayments, comorbidities and co-medications may help identifying those who were more likely to benefit from counseling.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. doi:10.1056/NEJMoa0802987 Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. doi:10.​1056/​NEJMoa0802987
2.
Zurück zum Zitat Dailey G, Kim MS, Lian JF (2002) Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 30(1):71–79PubMed Dailey G, Kim MS, Lian JF (2002) Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 30(1):71–79PubMed
3.
Zurück zum Zitat Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9):728–740PubMed Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9):728–740PubMed
4.
Zurück zum Zitat O’Shea MP, Teeling M, Bennett K (2013) An observational study examining the effect of comorbidity on the rates of persistence and adherence to newly initiated oral anti-hyperglycaemic agents. Pharmacoepidemiol Drug Saf 22(12):1336–1344. doi:10.1002/pds.3535 PubMed O’Shea MP, Teeling M, Bennett K (2013) An observational study examining the effect of comorbidity on the rates of persistence and adherence to newly initiated oral anti-hyperglycaemic agents. Pharmacoepidemiol Drug Saf 22(12):1336–1344. doi:10.​1002/​pds.​3535 PubMed
5.
Zurück zum Zitat Dezii CM, Kawabata H, Tran M (2002) Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 95(1):68–71PubMed Dezii CM, Kawabata H, Tran M (2002) Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 95(1):68–71PubMed
9.
Zurück zum Zitat Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G (2013) Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 15(1):55–61. doi:10.1111/j.1463-1326.2012.01674.x PubMed Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G (2013) Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 15(1):55–61. doi:10.​1111/​j.​1463-1326.​2012.​01674.​x PubMed
10.
Zurück zum Zitat Odegard PS, Capoccia K (2007) Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 33 (6):1014–1029. doi:10.1177/0145721707308407; discussion 1030-1011 Odegard PS, Capoccia K (2007) Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 33 (6):1014–1029. doi:10.​1177/​0145721707308407​; discussion 1030-1011
13.
Zurück zum Zitat Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848. doi:10.2147/IJGM.S36944 PubMedCentralPubMed Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848. doi:10.​2147/​IJGM.​S36944 PubMedCentralPubMed
14.
Zurück zum Zitat Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT (2003) Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 25(11):2958–2971PubMed Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT (2003) Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 25(11):2958–2971PubMed
15.
Zurück zum Zitat Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J (2006) Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29(9):1997–2002. doi:10.2337/dc06-0454 CrossRefPubMedCentralPubMed Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J (2006) Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29(9):1997–2002. doi:10.​2337/​dc06-0454 CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Aljasem LI, Peyrot M, Wissow L, Rubin RR (2001) The impact of barriers and self-efficacy on self-care behaviors in type 2 diabetes. Diabetes Educ 27(3):393–404PubMed Aljasem LI, Peyrot M, Wissow L, Rubin RR (2001) The impact of barriers and self-efficacy on self-care behaviors in type 2 diabetes. Diabetes Educ 27(3):393–404PubMed
17.
18.
Zurück zum Zitat Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D (2008) Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 10(Suppl. 1):25–32. doi:10.1111/j.1463-1326.2008.00882.x PubMed Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D (2008) Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 10(Suppl. 1):25–32. doi:10.​1111/​j.​1463-1326.​2008.​00882.​x PubMed
19.
Zurück zum Zitat No authors listed (1997) Implementation of the International statistical classification of diseases and related health problems, tenth revision (ICD-10). Epidemiol Bull 18(1):1–4 No authors listed (1997) Implementation of the International statistical classification of diseases and related health problems, tenth revision (ICD-10). Epidemiol Bull 18(1):1–4
20.
Zurück zum Zitat Hughes C (2010) ICD-9 update 2011: approaching the change to ICD-10. Fam Pract Manag 17(5):15–16PubMed Hughes C (2010) ICD-9 update 2011: approaching the change to ICD-10. Fam Pract Manag 17(5):15–16PubMed
21.
Zurück zum Zitat Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731–737PubMed Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731–737PubMed
22.
Zurück zum Zitat Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999–1009PubMed Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999–1009PubMed
23.
Zurück zum Zitat Dorais M, Chirovsky D, Ambegaonkar B, Sazonov V, Davies G, Grant S, Lelorier J (2010) Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can J Cardiol 26(7):e229–e235PubMedCentralPubMed Dorais M, Chirovsky D, Ambegaonkar B, Sazonov V, Davies G, Grant S, Lelorier J (2010) Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can J Cardiol 26(7):e229–e235PubMedCentralPubMed
24.
Zurück zum Zitat Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15 (8):565–574. doi:10.1002/pds.1230; discussion 575-567 Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15 (8):565–574. doi:10.​1002/​pds.​1230; discussion 575-567
26.
Zurück zum Zitat Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27(5):1218–1224CrossRefPubMed Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes Care 27(5):1218–1224CrossRefPubMed
27.
Zurück zum Zitat Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, Mauldin PD (2012) Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care 35(12):2533–2539. doi:10.2337/dc12-0572 CrossRefPubMedCentralPubMed Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, Mauldin PD (2012) Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care 35(12):2533–2539. doi:10.​2337/​dc12-0572 CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J (2005) Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 39(9):1401–1408. doi:10.1345/aph.1E548 PubMed Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J (2005) Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 39(9):1401–1408. doi:10.​1345/​aph.​1E548 PubMed
29.
Zurück zum Zitat Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J (2005) Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 61(9):667–674. doi:10.1007/s00228-005-0980-z PubMed Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J (2005) Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 61(9):667–674. doi:10.​1007/​s00228-005-0980-z PubMed
30.
Zurück zum Zitat Gibson TB, Song X, Alemayehu B, Wang SS, Waddell JL, Bouchard JR, Forma F (2010) Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag care 16(8):589–600PubMed Gibson TB, Song X, Alemayehu B, Wang SS, Waddell JL, Bouchard JR, Forma F (2010) Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag care 16(8):589–600PubMed
31.
Zurück zum Zitat White J (2004) The cost of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manag Health Outcomes 12(3):181–188 White J (2004) The cost of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in a managed care environment. Dis Manag Health Outcomes 12(3):181–188
34.
Zurück zum Zitat Colombi AM, Yu-Isenberg K, Priest J (2008) The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med 50(5):535–541. doi:10.1097/JOM.0b013e31816ed011 PubMed Colombi AM, Yu-Isenberg K, Priest J (2008) The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med 50(5):535–541. doi:10.​1097/​JOM.​0b013e31816ed011​ PubMed
35.
Zurück zum Zitat Hunt J, Rozenfeld Y, Shenolikar R (2009) Effect of patient medication cost share on adherence and glycemic control. Manag Care 18(7):47–53PubMed Hunt J, Rozenfeld Y, Shenolikar R (2009) Effect of patient medication cost share on adherence and glycemic control. Manag Care 18(7):47–53PubMed
36.
Zurück zum Zitat Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M (2010) Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull 36(2):428–435. doi:10.1093/schbul/sbn106 PubMedCentralPubMed Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M (2010) Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull 36(2):428–435. doi:10.​1093/​schbul/​sbn106 PubMedCentralPubMed
38.
Zurück zum Zitat Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43(3):413–422. doi:10.1345/aph.1L496 PubMed Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43(3):413–422. doi:10.​1345/​aph.​1L496 PubMed
Metadaten
Titel
Persistence and adherence to oral antidiabetics: a population-based cohort study
verfasst von
Patrice Simard
Nancy Presse
Louise Roy
Marc Dorais
Brian White-Guay
Agnès Räkel
Sylvie Perreault
Publikationsdatum
01.06.2015
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 3/2015
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0692-x

Weitere Artikel der Ausgabe 3/2015

Acta Diabetologica 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.